Cargando…
The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis
Background Cost and drug toxicity frequently deter the long-term use of anti-tumor necrosis factor (TNF) agents in ankylosing spondylitis (AS). Therefore, this study was conducted to observe long-term relief after the short-term administration of an anti-TNF agent. Methodology A one-year, prospectiv...
Autores principales: | Chopra, Arvind, Khadke, Nagnath, Saluja, Manjit, Kianifard, Toktam, Venugopalan, Anuradha, Gharia, Mihir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030650/ https://www.ncbi.nlm.nih.gov/pubmed/36960229 http://dx.doi.org/10.7759/cureus.36444 |
Ejemplares similares
-
Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019) -
Long term effectiveness of RA-1 as a monotherapy and in combination with disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis
por: Chopra, Arvind, et al.
Publicado: (2018) -
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019) -
Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach, Aziza, et al.
Publicado: (2014) -
Thoracic Discitis in Ankylosing Spondylitis
por: Maloney, Eamon, et al.
Publicado: (2018)